| scholarly article | Q13442814 |
| P2093 | author name string | Kazuma Tomizuka | |
| Takeshi Oshima | |||
| Tsutomu Okada | |||
| Makoto Kakitani | |||
| Yuichiro Kondo | |||
| Kengo Yamawaki | |||
| P2860 | cites work | A comparison of mechanical properties derived from multiple skeletal sites in mice. | Q51553347 |
| Bone Morphogenetic Proteins: A critical review | Q37801468 | ||
| First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. | Q38326323 | ||
| Inhibition of Notch1 signaling by Runx2 during osteoblast differentiation. | Q38482269 | ||
| Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis | Q39106423 | ||
| The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb | Q39526477 | ||
| A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health | Q39688975 | ||
| Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo | Q39695455 | ||
| Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption | Q39846980 | ||
| Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway | Q39956368 | ||
| Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer | Q44319244 | ||
| BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling | Q45065876 | ||
| Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women | Q45412595 | ||
| A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cells | Q48656274 | ||
| TGF-beta signal transduction | Q22003891 | ||
| Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses | Q24310450 | ||
| Regulation of muscle growth by multiple ligands signaling through activin type II receptors | Q24538732 | ||
| Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo | Q24555732 | ||
| A novel transgenic chimaeric mouse system for the rapid functional evaluation of genes encoding secreted proteins | Q24794416 | ||
| Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts | Q29036440 | ||
| Identification of the haematopoietic stem cell niche and control of the niche size | Q29615008 | ||
| Specificity and versatility in tgf-beta signaling through Smads | Q29616324 | ||
| Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. | Q30432180 | ||
| ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth | Q34096297 | ||
| A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers | Q34235483 | ||
| Mitogenic influence of human R-spondin1 on the intestinal epithelium | Q34444196 | ||
| Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice | Q34680057 | ||
| Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects | Q34792580 | ||
| BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury | Q34979181 | ||
| BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment | Q34992889 | ||
| Genetic analysis of the mammalian transforming growth factor-beta superfamily | Q35017076 | ||
| Consequences of knocking out BMP signaling in the mouse | Q35025212 | ||
| Sotatercept in patients with osteolytic lesions of multiple myeloma. | Q35035011 | ||
| Adult-specific systemic over-expression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII. | Q35035999 | ||
| The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations | Q35446158 | ||
| A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength | Q36132931 | ||
| Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation | Q36325743 | ||
| Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. | Q37203466 | ||
| Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation | Q37339719 | ||
| Humoral bone morphogenetic protein 2 is sufficient for inducing breast cancer microcalcification. | Q37400376 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 18849 | |
| P577 | publication date | 2016-01-06 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders | |
| P478 | volume | 6 |
Search more.